Elsevier

European Journal of Cancer

Volume 32, Issue 10, September 1996, Pages 1753-1757
European Journal of Cancer

Original paper
Rheumatoid arthritis and cancer risk

https://doi.org/10.1016/0959-8049(96)00210-9Get rights and content

Abstract

The aim of this study was to examine the cancer pattern in a large group of patients with rheumatoid arthritis (RA). A follow-up study of cancer incidence in RA was conducted within a cohort of 20 699 patients recorded in the Danish Hospital Discharge Register during 1977–1987 by linkage with the Danish Cancer Registry through 1991. There were consistent excesses of non-Hodgkin's lymphoma and Hodgkin's disease in both sexes and during both early and late periods of follow-up. Risks for lung cancer and non-melanoma skin cancer were also increased, with no predilection for any specific histological subtype, while risks for colorectal cancer and female breast cancer were reduced. The cancer pattern seen among Danish RA patients largely supports findings from two earlier Nordic investigations. Thus, there seem to be consistent positive associations between RA and non-Hodgkin's lymphoma, Hodgkin's disease and lung cancer and a consistent negative association with colorectal cancer.

References (30)

  • RI Fox et al.

    Potential role of Epstein-Barr virus in Sjögren's syndrome and rheumatoid arthritis

    J Rheumatol Suppl

    (1992)
  • G Gridley et al.

    Incidence of cancer among patients with rheumatoid arthritis

    J Natl Cancer Inst

    (1993)
  • Danish National Board Of Health
  • Danish National Board Of Health
  • HH Storm et al.
  • Cited by (362)

    • Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis

      2020, Pharmacological Research
      Citation Excerpt :

      Evidence-based recommendations for PsA treatment with NSAIDs, conventional synthetic DMARDs, and biological agents have been published but, although the clinical efficacy of biological treatment has been clearly established, there is still uncertainty regarding its potential adverse effects [68]. The risk of malignancy associated with PsA is still a controversial subject, but RA and other inflammatory joint diseases have been associated with an increased prevalence [23,69–71]. The aim of one of the first studies on the subject was to determine the prevalence of malignancy in 665 PsA patients prospectively followed up by the University of Toronto Psoriatic Arthritis Clinic from 1978 to 2004.

    • JAK-Inhibitors – A Story of Success and Adverse Events

      2024, Open Access Rheumatology: Research and Reviews
    View all citing articles on Scopus
    View full text